Name: mhc class i antigens in malignant cells: immune escape and response to immunotherapy (en Inglés)
Price: 159865.00 COP
Availability: InStock
Author: Aptsiauri, Natalia ; Garcia-Lora, Angel Miguel ; Cabrera, Teresa
ISBN: 9781461465423

portada mhc class i antigens in malignant cells: immune escape and response to immunotherapy (en Inglés)

mhc class i antigens in malignant cells: immune escape and response to immunotherapy (en Inglés)

Formato

Libro Físico

Autor

Natalia Aptsiauri

Angel Miguel Garcia-Lora

Teresa Cabrera

Editorial

Springer

Año

2013

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.6 x 15.0 x 0.8 cm

Peso

0.18 kg.

ISBN

1461465427

ISBN13

9781461465423

Categorías

Oncología
Inmunología
Biología molecular

mhc class i antigens in malignant cells: immune escape and response to immunotherapy (en Inglés)

Natalia Aptsiauri (Autor) · Angel Miguel Garcia-Lora (Autor) · Teresa Cabrera (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 14 a 20 días háb.

$ 319.729$ 159.865

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 159.865

¡Envío Gratis! Llega entre el 18 Ago y el 27 Ago a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "mhc class i antigens in malignant cells: immune escape and response to immunotherapy (en Inglés)"

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.